# A Study of Glucocorticoid Use to Evaluate Systematic Methylprednisolone Reduction in Patients With Rheumatoid Arthritis on Background RoActemra/Actemra (Tocilizumab) (ACT-ALONE)

> **NCT01219933** · PHASE4 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 68 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** methylprednisolone
- **DRUG:** tocilizumab [RoActemra/Actemra]

## Key facts

- **NCT ID:** NCT01219933
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-01
- **Primary completion:** 2013-03
- **Final completion:** 2013-03
- **Target enrollment:** 68 (ACTUAL)
- **Last updated:** 2015-01-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01219933

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01219933, "A Study of Glucocorticoid Use to Evaluate Systematic Methylprednisolone Reduction in Patients With Rheumatoid Arthritis on Background RoActemra/Actemra (Tocilizumab) (ACT-ALONE)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01219933. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*